Literature DB >> 17696195

Differential gene expression in melanocytic nevi with the V600E BRAF mutation.

Sandra Bloethner1, Erna Snellman, Justo Lorenzo Bermejo, Eva Hiripi, Andreas Gast, Ranjit K Thirumaran, Ruth Wellenreuther, Kari Hemminki, Rajiv Kumar.   

Abstract

We studied gene expression in 18 melanocytic nevi with and four nevi without the V600E mutation in the BRAF gene using HG-U133A 2.0 microarray with 22,277 transcripts. Data analysis revealed 92 genes up-regulated and 105 genes down-regulated in nevi with the mutation compared to nevi without mutation. Pathway analysis showed that differentially regulated genes mapped to 10 genetic networks. The major network included genes involved in cell death, cell cycle, and cellular growth and proliferation. Up-regulated genes in nevi with the mutation included CDKN2A, CDKN1C, and MITF; whereas down-regulated genes included those involved in apoptotic and other pathways. Principal component analysis identified 22 probe sets (20 genes) that caused separate segregation of nevi with and without mutations. In conclusion, our data showed differences in gene expression between nevi with and without the V600E BRAF mutation. Moreover, nevi with mutations showed over-expression of genes involved in melanocytic senescence and cell cycle inhibition. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696195     DOI: 10.1002/gcc.20488

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

1.  Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.

Authors:  S M Kumar; J Dai; S Li; R Yang; H Yu; K L Nathanson; S Liu; H Zhou; J Guo; X Xu
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

Review 2.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 3.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

Review 4.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Authors:  Rajasekharan Somasundaram; Jessie Villanueva; Meenhard Herlyn
Journal:  Adv Pharmacol       Date:  2012

5.  Molecular nevogenesis.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  Dermatol Res Pract       Date:  2011-04-06

6.  MGDB: a comprehensive database of genes involved in melanoma.

Authors:  Di Zhang; Rongrong Zhu; Hanqian Zhang; Chun-Hou Zheng; Junfeng Xia
Journal:  Database (Oxford)       Date:  2015-09-30       Impact factor: 3.451

7.  One Step Melanoma Surgery for Patient with Thick Primary Melanomas: "To Break the Rules, You Must First Master Them!"

Authors:  Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-02-09

Review 8.  The Conundrum of Genetic "Drivers" in Benign Conditions.

Authors:  Shumei Kato; Scott M Lippman; Keith T Flaherty; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2016-04-07       Impact factor: 13.506

9.  Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma.

Authors:  Elizabeth S Borden; Anngela C Adams; Kenneth H Buetow; Melissa A Wilson; Julie E Bauman; Clara Curiel-Lewandrowski; H-H Sherry Chow; Bonnie J LaFleur; Karen Taraszka Hastings
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.575

Review 10.  The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.

Authors:  Barbara Montico; Giorgio Giurato; Giovanni Pecoraro; Annamaria Salvati; Alessia Covre; Francesca Colizzi; Agostino Steffan; Alessandro Weisz; Michele Maio; Luca Sigalotti; Elisabetta Fratta
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.